This company listing is no longer active
290A Stock Overview
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Chinook Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$36.40 |
| 52 Week High | US$37.40 |
| 52 Week Low | US$16.80 |
| Beta | 0.67 |
| 1 Month Change | 3.41% |
| 3 Month Change | 75.00% |
| 1 Year Change | 89.58% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 197.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| 290A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.6% | -0.6% | 0.8% |
| 1Y | 89.6% | -12.3% | 14.6% |
Return vs Industry: 290A exceeded the German Biotechs industry which returned -7.5% over the past year.
Return vs Market: 290A exceeded the German Market which returned 1.6% over the past year.
Price Volatility
| 290A volatility | |
|---|---|
| 290A Average Weekly Movement | 20.0% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 290A's share price has been volatile over the past 3 months.
Volatility Over Time: 290A's weekly volatility has increased from 11% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 214 | Eric Dobmeier | www.chinooktx.com |
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company’s lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases.
Chinook Therapeutics, Inc. Fundamentals Summary
| 290A fundamental statistics | |
|---|---|
| Market cap | €2.65b |
| Earnings (TTM) | -€224.40m |
| Revenue (TTM) | €5.34m |
495.8x
P/S Ratio-11.8x
P/E RatioIs 290A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 290A income statement (TTM) | |
|---|---|
| Revenue | US$5.85m |
| Cost of Revenue | US$193.72m |
| Gross Profit | -US$187.87m |
| Other Expenses | US$57.79m |
| Earnings | -US$245.65m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.42 |
| Gross Margin | -3,211.95% |
| Net Profit Margin | -4,199.93% |
| Debt/Equity Ratio | 0% |
How did 290A perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/08/11 01:08 |
| End of Day Share Price | 2023/08/10 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Chinook Therapeutics, Inc. is covered by 11 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Antonia Borovina | Bloom Burton & Co. |
| Charles Duncan | Cantor Fitzgerald & Co. |
| Joshua Schimmer | Evercore ISI |